Most primary care networks have ARRS-funded pharmacy roles in place by now. The harder question for PCN leaders and budget holders is no longer whether to use the funding, but whether the spend is actually returning clinical value. An ARRS role can look busy on paper and still leave the medication review backlog growing, high-risk drug monitoring slipping, and GP time draining away on prescription queries that should never reach a prescriber.
An ARRS pharmacist ROI audit is a structured way to answer that question. It moves the conversation from “we have a pharmacist” to “here is what that pharmacist is changing, and here is the evidence”. This post sets out what to measure, the warning signs of an under-used role, and how a managed clinical service changes the picture by making the return visible and repeatable. If you want the general case for turning ARRS funding into clinical value, that is a separate topic; the focus here is evaluation and recovery of value you may already be leaving on the table.
Why an ARRS role can underdeliver without anyone noticing
ARRS spend rarely fails loudly. It underdelivers quietly, in ways that are easy to miss until a CQC inspection, a significant event, or a budget review forces a look at the detail. A few common patterns sit behind a disappointing return.
- The role is absorbed into reactive work. Days fill with same-day queries and discharge reconciliation, and the planned, higher-value clinical work never gets scheduled.
- Scope creep into administrative tasks. A clinically trained pharmacist spending large parts of the week on tasks a coordinator or technician could handle is poor value, however willing the individual.
- No clear clinical priorities. Without an agreed list of what to target first, effort spreads thinly and nothing measurable shifts.
- Gaps when the person is away. A single role with no continuity arrangement means monitoring and reviews stall during leave or turnover, and the backlog rebuilds.
- Activity is recorded, outcomes are not. The PCN can say how many appointments happened but cannot say what changed for patients or for the practice.
None of these are individual failings. They are usually structural, and they are the things an audit is designed to surface.
What to actually measure in an ARRS pharmacist ROI audit
Return on an ARRS clinical role is not a single number. It is a small set of clinical and operational measures that, taken together, tell you whether the investment is doing what you need. Pull a baseline first, then track the trend over a defined period.
Backlog cleared and kept clear
The most visible return is workload that no longer lands on GPs. Look at the structured medication review queue, the volume of prescription queries reaching a prescriber, and the discharge and clinic-letter actions waiting to be processed. A role delivering value shows a backlog falling and then holding steady, not a one-off clear-down that quietly refills. Our work on the clinical medication review side is one of the clearest places to see this trend.
Monitoring kept safe
High-risk drug monitoring is where an under-used role stops being an efficiency problem and becomes a patient safety one. Audit the proportion of patients on relevant medicines who are within their monitoring window: for example DMARDs, lithium, anticoagulants, amiodarone and similar. Overdue counts that fall and stay low are strong evidence of return. Counts that drift upward, even while appointment numbers look healthy, are a red flag. Structured high-risk drug monitoring should be a defined, tracked workstream, not something fitted in around everything else.
QOF and PCN incentive contribution
Clinical pharmacy work touches a lot of QOF and the wider PCN incentive picture, particularly around medicines, long-term conditions and reviews. Look at where the pharmacist’s activity maps onto the indicators your practices are working towards, and whether achievement is improving in those areas. Check the current detail against the official BMA and NHS England documentation, because the frameworks change and earlier schemes have been folded or wound down.
Prescribing quality and savings
Medicines optimisation produces some of the most defensible ROI because it shows up in prescribing data. Audit changes in the safety and cost-effectiveness of prescribing the pharmacist has influenced: deprescribing where appropriate, switches to preferred formulary choices, reduced waste, and safer combinations. A medicines optimisation programme with clear before-and-after data turns a soft claim into a number you can put in front of a budget holder.
GP and team time recovered
Recovered clinician time is real value even though it is harder to price. Estimate it from the work the pharmacist now owns end to end: medication queries resolved without a GP, reviews completed independently, and monitoring managed without prescriber input. If GPs still feel they are carrying the same medicines workload, the role is not yet returning what it should, regardless of activity figures.
Signs your ARRS role is under-used
You do not always need a full data pull to suspect a poor return. Several signals tend to show up first.
- You can describe the role’s activity but not its outcomes.
- The medication review or query backlog is the same size, or larger, than a year ago.
- Monitoring overdue lists are creeping up while clinics still run.
- The pharmacist spends significant time on tasks that do not need a pharmacist.
- Clinical work stops when the individual is on leave, and nobody is accountable for it in the meantime.
- There is no agreed list of clinical priorities the role is working through.
- Governance for the clinical work is unclear, or quietly sits with already-stretched GPs.
Any one of these is worth a closer look. Several together usually mean value is being left on the table that a different delivery model could recover.
How a managed clinical service changes the return
The way an ARRS role is delivered has a large effect on the return it produces. A staffing or agency arrangement places a person and leaves the PCN to manage, supervise, govern and cover them. When that person is busy, away, or moves on, the value pauses and the backlog rebuilds. Continuity, governance and measurement become the network’s problem.
A managed clinical service works differently. Virtual Pharmacist delivers clinical pharmacy work remotely inside the practice’s own EMIS, SystmOne, Vision or Medicus system, and is accountable for that service, including its clinical governance, supervision and quality assurance. We are not supplying staff or capacity for you to manage; we are delivering a defined service against agreed clinical priorities, with the assurance wrapped around it. For an audit, several differences matter directly.
- Outcomes are designed in. Work is scoped against clinical priorities from the start, so the audit measures from a defined plan rather than reverse-engineering value after the fact.
- Continuity is built in. Delivery sits with a national team of GPhC-registered pharmacists and pharmacy technicians, so reviews and monitoring keep moving through leave and turnover instead of stalling.
- Governance is held by the service. Virtual Pharmacist is accountable for the quality and governance of its service. Clinicians remain professionally accountable, and the practice retains its own duties. CQC registration requirements depend on the activities and delivery arrangements. Our approach to clinical governance and data security means assurance is part of the service, not an extra task for your GPs.
- The right work goes to the right person. Splitting clinical and technical tasks appropriately, with support from pharmacy technician work, keeps clinically trained time on clinical work and lifts the value per pound.
- Reporting evidences the return. Because measurement is part of how the service runs, the backlog, monitoring, QOF contribution and prescribing changes are visible throughout the year.
The practical effect is that the audit becomes routine. Instead of commissioning an annual investigation into whether the spend worked, you get a continuous view of what the service is changing, which is exactly what a budget holder needs at review time.
Turning the audit into action
An audit is only useful if it leads somewhere. Once you have a baseline, agree a short list of clinical priorities, decide who is accountable for each, and set the measures you will track. Then revisit them on a regular cycle. If the current arrangement is delivering against those priorities, you have the evidence to defend the spend. If it is not, you have a clear, specific brief for improving it, whether by re-scoping the role or by moving to a delivery model that holds governance and continuity for you.
If you want to see how a managed service maps onto your existing ARRS spend, our ARRS support and PCN management support pages set out how the work is delivered and assured across a network.
Frequently asked questions
What does an ARRS pharmacist ROI audit actually look at?
It looks at clinical and operational return rather than activity alone. The core measures are the medication review and query backlog, whether high-risk drug monitoring is kept within safe windows, the role’s contribution to QOF and PCN incentives, prescribing quality and savings, and the GP and team time recovered. You take a baseline, then track the trend over a defined period.
How do I know if my ARRS pharmacist role is under-used?
Common signs include being able to describe activity but not outcomes, a backlog that is the same size or larger than a year ago, monitoring overdue lists creeping up, a clinically trained pharmacist spending a lot of time on tasks that do not need a pharmacist, and clinical work stalling whenever the person is on leave. Several of these together usually mean value is being lost.
Does using a managed service affect our CQC position?
Professional regulation and service registration are different questions. Pharmacists are regulated by the GPhC. Whether a provider needs CQC registration depends on the activities delivered and who is responsible for carrying them on, including the subcontracting arrangement. Confirm that position and the responsibilities of each organisation before the service starts; work delivered in a practice is not automatically covered by its registration.
How is a managed service different from employing or hiring a pharmacist into the role?
A staffing or agency model places a person and leaves the PCN to direct, supervise, govern and cover them. A managed clinical service delivers a defined service against agreed priorities and is accountable for it, including its clinical governance, supervision and quality assurance. It provides continuity through a national team, so reviews and monitoring keep moving during leave or turnover. Virtual Pharmacist supplies a managed clinical service, not staff.
How quickly can an audit show whether the spend is working?
A baseline can be pulled fairly quickly from your clinical system, but return is best judged as a trend, so allow a defined review period to see whether the backlog falls and holds, monitoring stays safe, and prescribing improves. With a managed service, this reporting is part of how the work runs, so the picture stays current rather than being reconstructed once a year.
If you are a GP practice, PCN or ICB weighing up whether your ARRS pharmacist spend is delivering the clinical return it should, contact Virtual Pharmacist to discuss your needs. We will talk through what to measure and how a managed, remote clinical service can evidence and improve the value you are getting.